2Jin H,Meyer JM,Jeste DV.A typ ical antip sychotics and glacose dysregulation:a systematic review[J].Schizophr Res,2004,71(2):195-212.
3Lieberman JA,Tollefson G,Tohen M,et al,Comparative efficacy ang saftey of atipical and conven tional antipsychotic drugs in firstepisode psychosis:A randomized,double-blind trial of olanzapine versus haloperidol[J],Am J Psychiatry,2003,160(8):1401-1403.
6Merlkersson KI,Hulting AL,Brisma KE.Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses[J].J Clin Psychiatry,1999,60(11):783-786.
2Despres JP. Health consequences of visceral obesity. Ann Med,2001,33(8) :534.
3Kooy KVD, Leenen R, Seidell JC, et al. Abdominal diameters as indicators of visceral fat: comparison between magnetic imaging and anthropometry. The British Journal of Nutrition, 1993,70(1):47.
4Fridewald WT, Levi RI, Fredrickson DN. Estimation of concentration of low density lipoprotein cholesterol in plasma without use of the preparation ultracentrifuge. Clin Chem, 1972,18(5) :499.
6Taylor DM, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand, 2000,101(6) :416.
7Thakore JH, Mann JN, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord, 2002,26( 1 ): 137.
8Ledoux M, Lambert J, Reeder B, et al. Correlation between cardiovascular disease risk factors and simple anthropometric measures. CMA J,1997,157(Suppl): s46 ～ s52.
9Baptista T, Kin NM, Beaulieu S, et al. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms,management and research perspectives. Pharmacopsychiatry, 2002, 35(6):205.
10He LP, Mears D, Atwater I, Kitasato H. Glucagon induces suppression of ATP-sensitive K+ channel activity through a Ca2+/calmodulin-dependent pathway in mouse pancreatic beta-cells. J Membr Biol, 1998, 166(3) :237.
